NCAM1 and stroke disorder: Thus, based on our previous investigations and the present study, we propose a new strategy for personalized cell-mediated gene therapy for stroke treatment based on the intravenous infusion of the autologous GEL temporally secreting neuroprotective factors (VEGF, GDNF, and NCAM).